Z Squared Inc. (ZSQR) stock
Close on Nov 17, 2026Market cap $102.82MP/E –Yield –
Z Squared Inc. grew revenue 4348.2% to $2.80M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $102.82M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $102.82M
- P/E ratio
- –
- Price to sales
- 36.76
- Price to book
- 0.78
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.80M
- Net income
- -$17.96M
- EPS, diluted
- -$0.39
- Book value per share
- $2.66
- Diluted shares
- 50M
Trading
- Previous close
- $2.22
- Open
- $2.22
- Day's range
- $1.83 – $2.26
- Volume
- 402,663
- Average volume (20 days)
- 332,906
- Index membership
- Russell 2000 (since Jun 2026)
- 52-week range
- $1.83 – $21.41
- RSI (14 days)
- 28.0
- Volatility (1 year)
- 116.6%
- Relative volume
- 0.95×
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZSQR | S&P 500 | Difference | ZSQR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.9% | -4.0% | −47.9 pts | ||
| 3 months | -49.7% | -5.0% | −44.8 pts | ||
| Year to date | -86.4% | +8.2% | −94.6 pts | ||
| 1 year | -87.2% | +11.2% | −98.4 pts | ||
| 3 years | -92.0% | +68.5% | −160.5 pts | -57.0% | +19.0% |
| 5 years | -99.0% | +67.3% | −166.3 pts | -60.4% | +10.8% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases Z Squared filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- Update
- Update
About Z Squared
Finance Services
Coeptis Therapeutics Holdings, Inc. operates as a biopharmaceutical and technology company structured across two main divisions. Its biopharmaceutical division develops cell therapy platforms, including natural killer cell therapies, chimeric antigen receptor technologies, and diagnostic tools designed for cancer, autoimmune conditions, and infectious diseases. Its technology division provides artificial intelligence marketing software and robotic process automation tools to optimize enterprise workflows. The company directs its healthcare solutions toward patients suffering from hematologic malignancies and viral infections, while its technology services cater to corporate clients seeking advertising campaigns and digital webinar solutions.
Company profile, executives and historyZ Squared stock: common questions
What is Z Squared's stock price?
ZSQR closed at $1.94 on Nov 17, 2026, down 12.61% on the day. Over the past 52 weeks it traded between $1.83 and $21.41.
What is Z Squared's market cap?
Z Squared was worth $102.82M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.
What is ZSQR's P/E ratio?
Z Squared lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.39), so it has no meaningful P/E ratio.
How much revenue does Z Squared make?
Z Squared reported revenue of $2.80M for the twelve months to Jun 30, 2026, up 4348.2% from a year earlier.
Does Z Squared pay a dividend?
No. Z Squared has not paid a cash dividend over the last twelve months.
How has ZSQR stock performed over the past year?
Including dividends, ZSQR returned -87.2% over the past year, against +11.2% for the S&P 500.
How many ZSQR shares are sold short?
3M shares were sold short at the latest FINRA report, 7.13% of the float, or 10.7 days of average trading volume.
Who are Z Squared's competitors?
Companies most similar to Z Squared by business, industry and size include AGPU, BNBX, AURE, TAOX, BNKK.
See a number that looks wrong?